Plandaí Biotechnology, Inc.

PLPLOTCFinancial Services● Active

$0.00

+$0.00(+900.00%)

Market Cap$4488953

P/E Ratio—

52W High$0.0001

52W Low$0.00001

Avg Volume17K

Open$0.00

Beta9.73

Free Cash Flow Financials Revenue

Plandaí Biotechnology, Inc. (PLPL) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

PLPL · free cash flow · updated Jun 9, 2026

Core FCF metrics

PLPL · FCF · TTM · margin & CAGR

Free cash flow was $15.6M for FY2024 (fiscal year ending 2024-06-30), up 2702.3% year-over-year

FY2024 Free Cash Flow$15.6M▲ +2702.3% YoY

Trailing 12M (TTM)$15.6Mtrailing 4 quarters sum

FCF Margin——

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 9, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

PLPL · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2024Latest$15.6M(0M)$15.6M▲ +2702.3%—

FY2023$558,114(0M)$558,112▼ 92.0%—

FY2022$7.0M(0M)$7.0M▲ +104444.5%—

FY2021−$6,675(0M)−$6,675——

FY2020$0(0M)$0▲ +100.0%—

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

PLPL · P/FCF · FCF yield · FCF per share

Plandaí Biotechnology, Inc. (PLPL) trades at a FCF yield of 0.00% and a price-to-free-cash-flow ratio of N/A. FCF per share stands at $0.00, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.

FCF Yield (TTM)

0.00%

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

$0.00

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

x0.0

Enterprise Value basis

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2024 · 2024-06-30

Cash flow statement summary

PLPL · cash flow statement · operating / investing / financing

For FY2024, Plandaí Biotechnology, Inc. generated $15.6M in operating cash flow and spent 0M in capital expenditures, yielding $15.6M in free cash flow.

Operating Activities

+$15.6M

Cash from core business operations

2024-06-30

Investing Activities

−$0.1M

CapEx, acquisitions & investments

2024-06-30

Financing Activities

−$15.5M

Buybacks, dividends & debt

2024-06-30

FCF FormulaOperating CF ($15.6M) − |CapEx| (0M) = FCF ($15.6M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Financial Services)

PLPL vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Plandaí Biotechnology, Inc.YOU

PLPL

$15.6M+2702.3%—

Berkshire Hathaway Inc.

BRK-A

$25.04B+115.6%6.7%

25%

Berkshire Hathaway Inc.

Mastercard Incorporated

$16.91B+18.2%51.6%

17%

Financial Services · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Plandaí Biotechnology, Inc. (PLPL) reported free cash flow of $15.6M for FY2024 (fiscal year ending 2024-06-30), up 2702.3% year-over-year.

Based on available data, Plandaí Biotechnology, Inc. has maintained positive free cash flow for at least 5 fiscal year(s). FCF peaked at $15.6M in FY2024.

Plandaí Biotechnology, Inc.'s FCF yield is 0.00% and price-to-FCF ratio is N/A for FY2024, based on the latest available data.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

PLPL free cash flow · 8 questions

Plandaí Biotechnology, Inc. free cash flow was $15.6M for FY2024, up 2702.3% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $15.6M.

PLPL free cash flowPLPL FCFPLPL FCF 2024PLPL free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Plandaí Biotechnology, Inc. · Plandaí Biotechnology, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026